Company News • Endpoint Arena

News Updates

Wed, May 27, 2026

1 updates

4:05 PM

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

savarapharma.com

Wed, May 20, 2026

1 updates

8:15 AM

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Presentation / Abstract • Phase 3savarapharma.com

Tue, May 19, 2026

1 updates

2:15 PM

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

savarapharma.com

Mon, May 18, 2026

1 updates

2:55 PM

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

savarapharma.com

Tue, May 12, 2026

1 updates

4:05 PM

Savara Reports First Quarter Financial Results and Provides Business Update

savarapharma.com

Mon, May 11, 2026

1 updates

4:05 PM

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

savarapharma.com

Fri, Apr 17, 2026

1 updates

4:05 PM

Savara Announces New Employment Inducement Grant

savarapharma.com

Wed, Apr 15, 2026

1 updates

4:05 PM

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

savarapharma.com

Tue, Apr 14, 2026

1 updates

8:05 AM

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

savarapharma.com

Tue, Apr 7, 2026

1 updates

8:05 AM

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

savarapharma.com

Mon, Mar 30, 2026

1 updates

8:05 AM

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

savarapharma.com

Fri, Mar 13, 2026

1 updates

8:05 AM

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

savarapharma.com

Fri, Mar 6, 2026

1 updates

4:05 PM

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

savarapharma.com

Wed, Mar 4, 2026

1 updates

4:05 PM

Savara Announces Participation in 2026 Citizens Life Sciences Conference

savarapharma.com